Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

477 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
New insights into the antiviral effects of chloroquine.
Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. Savarino A, et al. Lancet Infect Dis. 2006 Feb;6(2):67-9. doi: 10.1016/S1473-3099(06)70361-9. Lancet Infect Dis. 2006. PMID: 16439323 Free PMC article. No abstract available.
Effects of chloroquine on viral infections: an old drug against today's diseases?
Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Savarino A, et al. Lancet Infect Dis. 2003 Nov;3(11):722-7. doi: 10.1016/s1473-3099(03)00806-5. Lancet Infect Dis. 2003. PMID: 14592603 Free PMC article. Review.
Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects.
Cassone A, Tacconelli E, De Bernardis F, Tumbarello M, Torosantucci A, Chiani P, Cauda R. Cassone A, et al. J Infect Dis. 2002 Jan 15;185(2):188-95. doi: 10.1086/338445. Epub 2002 Jan 3. J Infect Dis. 2002. PMID: 11807692
HIV infection, HAART, and endothelial adhesion molecules: current perspectives.
de Gaetano Donati K, Rabagliati R, Iacoviello L, Cauda R. de Gaetano Donati K, et al. Lancet Infect Dis. 2004 Apr;4(4):213-22. doi: 10.1016/S1473-3099(04)00971-5. Lancet Infect Dis. 2004. PMID: 15050939 Review.
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine.
De Luca A, Giambenedetto SD, Trotta MP, Colafigli M, Prosperi M, Ruiz L, Baxter J, Clevenbergh P, Cauda R, Perno CF, Antinori A. De Luca A, et al. J Infect Dis. 2007 Dec 1;196(11):1645-53. doi: 10.1086/522231. Epub 2007 Oct 26. J Infect Dis. 2007. PMID: 18008248

The best correlation with response was found with the derived score (M41L x 2) + E44D/A/G + T69D/S/N/A + (L210W x 2) + T215Y or revertants + L228H/R - D123E/N/G/S, by use of which viruses were categorized as being susceptible (score < or =0), as having intermediate resi

The best correlation with response was found with the derived score (M41L x 2) + E44D/A/G + T69D/S/N/A + (L210W x 2) + T215Y or revertants + …
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads.
Cozzi-Lepri A, De Luca A, Phillips AN, Bongiovanni M, Di Giambenedetto S, Mena M, Moioli MC, Arlotti M, Sighinolfi L, Narciso P, Lichtner M, Cauda R, Monforte Ad; ICoNA Study Group; UCSC-Roma HIV Cohort Study Group; IMIT Study Group. Cozzi-Lepri A, et al. J Infect Dis. 2006 Jul 1;194(1):20-8. doi: 10.1086/504265. Epub 2006 May 16. J Infect Dis. 2006. PMID: 16741878 Clinical Trial.
Risks and benefits of chloroquine use in anticancer strategies.
Savarino A, Lucia MB, Giordano F, Cauda R. Savarino A, et al. Lancet Oncol. 2006 Oct;7(10):792-3. doi: 10.1016/S1470-2045(06)70875-0. Lancet Oncol. 2006. PMID: 17012039 No abstract available.
On the use of chloroquine for chikungunya.
Savarino A, Cauda R, Cassone A. Savarino A, et al. Lancet Infect Dis. 2007 Oct;7(10):633. doi: 10.1016/S1473-3099(07)70217-7. Lancet Infect Dis. 2007. PMID: 17897603 Free PMC article. No abstract available.
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection.
Fabbiani M, Di Giambenedetto S, Cingolani A, Fanti I, Colafigli M, Tamburrini E, Cauda R, Navarra P, De Luca A, Murri R. Fabbiani M, et al. Infect Dis (Lond). 2016;48(1):48-55. doi: 10.3109/23744235.2015.1082034. Epub 2015 Sep 2. Infect Dis (Lond). 2016. PMID: 26329383
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
Fabbiani M, Mondi A, Colafigli M, D'Ettorre G, Paoletti F, D'Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S. Fabbiani M, et al. Scand J Infect Dis. 2014 Jan;46(1):34-45. doi: 10.3109/00365548.2013.840920. Epub 2013 Oct 28. Scand J Infect Dis. 2014. PMID: 24161018 Clinical Trial.
477 results
Jump to page
Feedback